Cargando…
Ceftazidime-Avibactam Treatment for Klebsiella pneumoniae Bacteremia in Preterm Infants in NICU: A Clinical Experience
Ceftazidime/avibactam (CAZ/AVI) is an antibiotic combination approved for the treatment of several infections caused by multi-drug resistant (MDR) Gram-negative bacteria. Neonates admitted to the Neonatal Intensive Care Unit (NICU) are at high risk of developing bacterial infections, and the choice...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10376358/ https://www.ncbi.nlm.nih.gov/pubmed/37508265 http://dx.doi.org/10.3390/antibiotics12071169 |
_version_ | 1785079251458850816 |
---|---|
author | Marino, Andrea Pulvirenti, Sarah Campanella, Edoardo Stracquadanio, Stefano Ceccarelli, Manuela Micali, Cristina Tina, Lucia Gabriella Di Dio, Giovanna Stefani, Stefania Cacopardo, Bruno Nunnari, Giuseppe |
author_facet | Marino, Andrea Pulvirenti, Sarah Campanella, Edoardo Stracquadanio, Stefano Ceccarelli, Manuela Micali, Cristina Tina, Lucia Gabriella Di Dio, Giovanna Stefani, Stefania Cacopardo, Bruno Nunnari, Giuseppe |
author_sort | Marino, Andrea |
collection | PubMed |
description | Ceftazidime/avibactam (CAZ/AVI) is an antibiotic combination approved for the treatment of several infections caused by multi-drug resistant (MDR) Gram-negative bacteria. Neonates admitted to the Neonatal Intensive Care Unit (NICU) are at high risk of developing bacterial infections, and the choice of appropriate antibiotics is crucial. However, the use of antibiotics in neonates carries risks such as antibiotic resistance and disruption of gut microbiota. This study aimed to assess the safety and efficacy of CAZ/AVI in preterm infants admitted to the NICU. Retrospective data from preterm infants with Klebsiella pneumoniae bacteremia who received CAZ/AVI were analyzed. Clinical and microbiological responses, adverse events, and outcomes were evaluated. Eight patients were included in the study, all of whom showed clinical improvement and achieved microbiological cure with CAZ/AVI treatment. No adverse drug reactions were reported. Previous antibiotic therapies failed to improve the neonates’ condition, and CAZ/AVI was initiated based on clinical deterioration and epidemiological considerations. The median duration of CAZ/AVI treatment was 14 days, and combination therapy with fosfomycin or amikacin was administered. Previous case reports have also shown positive outcomes with CAZ/AVI in neonates. However, larger trials are needed to further investigate the safety and efficacy of CAZ/AVI in this population. |
format | Online Article Text |
id | pubmed-10376358 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103763582023-07-29 Ceftazidime-Avibactam Treatment for Klebsiella pneumoniae Bacteremia in Preterm Infants in NICU: A Clinical Experience Marino, Andrea Pulvirenti, Sarah Campanella, Edoardo Stracquadanio, Stefano Ceccarelli, Manuela Micali, Cristina Tina, Lucia Gabriella Di Dio, Giovanna Stefani, Stefania Cacopardo, Bruno Nunnari, Giuseppe Antibiotics (Basel) Article Ceftazidime/avibactam (CAZ/AVI) is an antibiotic combination approved for the treatment of several infections caused by multi-drug resistant (MDR) Gram-negative bacteria. Neonates admitted to the Neonatal Intensive Care Unit (NICU) are at high risk of developing bacterial infections, and the choice of appropriate antibiotics is crucial. However, the use of antibiotics in neonates carries risks such as antibiotic resistance and disruption of gut microbiota. This study aimed to assess the safety and efficacy of CAZ/AVI in preterm infants admitted to the NICU. Retrospective data from preterm infants with Klebsiella pneumoniae bacteremia who received CAZ/AVI were analyzed. Clinical and microbiological responses, adverse events, and outcomes were evaluated. Eight patients were included in the study, all of whom showed clinical improvement and achieved microbiological cure with CAZ/AVI treatment. No adverse drug reactions were reported. Previous antibiotic therapies failed to improve the neonates’ condition, and CAZ/AVI was initiated based on clinical deterioration and epidemiological considerations. The median duration of CAZ/AVI treatment was 14 days, and combination therapy with fosfomycin or amikacin was administered. Previous case reports have also shown positive outcomes with CAZ/AVI in neonates. However, larger trials are needed to further investigate the safety and efficacy of CAZ/AVI in this population. MDPI 2023-07-10 /pmc/articles/PMC10376358/ /pubmed/37508265 http://dx.doi.org/10.3390/antibiotics12071169 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Marino, Andrea Pulvirenti, Sarah Campanella, Edoardo Stracquadanio, Stefano Ceccarelli, Manuela Micali, Cristina Tina, Lucia Gabriella Di Dio, Giovanna Stefani, Stefania Cacopardo, Bruno Nunnari, Giuseppe Ceftazidime-Avibactam Treatment for Klebsiella pneumoniae Bacteremia in Preterm Infants in NICU: A Clinical Experience |
title | Ceftazidime-Avibactam Treatment for Klebsiella pneumoniae Bacteremia in Preterm Infants in NICU: A Clinical Experience |
title_full | Ceftazidime-Avibactam Treatment for Klebsiella pneumoniae Bacteremia in Preterm Infants in NICU: A Clinical Experience |
title_fullStr | Ceftazidime-Avibactam Treatment for Klebsiella pneumoniae Bacteremia in Preterm Infants in NICU: A Clinical Experience |
title_full_unstemmed | Ceftazidime-Avibactam Treatment for Klebsiella pneumoniae Bacteremia in Preterm Infants in NICU: A Clinical Experience |
title_short | Ceftazidime-Avibactam Treatment for Klebsiella pneumoniae Bacteremia in Preterm Infants in NICU: A Clinical Experience |
title_sort | ceftazidime-avibactam treatment for klebsiella pneumoniae bacteremia in preterm infants in nicu: a clinical experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10376358/ https://www.ncbi.nlm.nih.gov/pubmed/37508265 http://dx.doi.org/10.3390/antibiotics12071169 |
work_keys_str_mv | AT marinoandrea ceftazidimeavibactamtreatmentforklebsiellapneumoniaebacteremiainpreterminfantsinnicuaclinicalexperience AT pulvirentisarah ceftazidimeavibactamtreatmentforklebsiellapneumoniaebacteremiainpreterminfantsinnicuaclinicalexperience AT campanellaedoardo ceftazidimeavibactamtreatmentforklebsiellapneumoniaebacteremiainpreterminfantsinnicuaclinicalexperience AT stracquadaniostefano ceftazidimeavibactamtreatmentforklebsiellapneumoniaebacteremiainpreterminfantsinnicuaclinicalexperience AT ceccarellimanuela ceftazidimeavibactamtreatmentforklebsiellapneumoniaebacteremiainpreterminfantsinnicuaclinicalexperience AT micalicristina ceftazidimeavibactamtreatmentforklebsiellapneumoniaebacteremiainpreterminfantsinnicuaclinicalexperience AT tinaluciagabriella ceftazidimeavibactamtreatmentforklebsiellapneumoniaebacteremiainpreterminfantsinnicuaclinicalexperience AT didiogiovanna ceftazidimeavibactamtreatmentforklebsiellapneumoniaebacteremiainpreterminfantsinnicuaclinicalexperience AT stefanistefania ceftazidimeavibactamtreatmentforklebsiellapneumoniaebacteremiainpreterminfantsinnicuaclinicalexperience AT cacopardobruno ceftazidimeavibactamtreatmentforklebsiellapneumoniaebacteremiainpreterminfantsinnicuaclinicalexperience AT nunnarigiuseppe ceftazidimeavibactamtreatmentforklebsiellapneumoniaebacteremiainpreterminfantsinnicuaclinicalexperience |